Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


For the Patient
Educational Resources
Clinical Trial Information
Professional Services



 

AMP 511

Design:

An Open-Label Study of Poly I: Poly C12U (Ampligen®) in Patients with Severely Debilitating Chronic Fatigue Syndrome (CFS) / Myalgic Encephalomyelitis (ME). The FDA approved the study for cost recovery. Patients enrolled in the study are responsible for costs related to the therapy, e.g., drug cost, infusion cost, cost of supplies, diagnostic and other laboratory testing.

 

Eligibility:
Subjects who meet the following criteria may be eligible for study participation:

  1. Diagnosis of Chronic Fatigue Syndrome ( 12 months) as defined by the 1988 CDC case definition of CFS
     

  2. Adults ages 18 to 65 years of age.
     

  3. Karnofsky Performance Score from 20 to 60 during baseline.

Status:
The study is open to enrollment.

Locations:
Charlotte, NC
Incline Village, NV
Salt Lake City, UT


Please contact Hemispherx Biopharma for additional information regarding trial locations and site contacts:


By Fax: 215-988-1739
By E-Mail: trialinfo@hemispherx.net
By Mail: Hemispherx Biopharma, Inc.
One Penn Center
1617 JFK Blvd., 6th Floor
Philadelphia, PA 19103
 

 
Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.